Mizagliflozin
|
|
|
- CAS号:
- 666843-10-3
- 英文名:
- Mizagliflozin
- 英文别名:
- KGA3235;KGA 3235;KGA-3235;GSK1614235;GSK-1614235;GSK 1614235;Mizagliflozin;DSP-3235 free base;KGA-3235 free base;GSK-1614235 free base
- 中文名:
- Mizagliflozin
- 中文别名:
- DSP-3235;化合物MIZAGLIFLOZIN;3 - ((3-(4 - ((5-异丙基-3 - (((2S,3R,4S,5S,6R)-3,4,5-三羟基-6-(羟甲基)四氢-2H-吡喃 2-基)氧基)-1H-吡唑-4-基)甲基)-3-甲基苯氧基)丙基)氨基)-2,2-二甲基丙酰胺
- CBNumber:
- CB34919871
- 分子式:
- C28H44N4O8
- 分子量:
- 564.68
- MOL File:
- 666843-10-3.mol
|
|
|
Mizagliflozin化学性质
-
沸点:
-
837.0±65.0 °C(Predicted)
-
|
-
密度:
-
1.274±0.06 g/cm3(Predicted)
-
|
-
储存条件:
-
4°C, protect from light
-
|
-
溶解度:
-
Methanol: 250 mg/mL (442.74 mM); DMSO: 100 mg/mL (177.09 mM)
-
|
-
酸度系数(pKa):
-
12.65±0.70(Predicted)
-
|
Mizagliflozin性质、用途与生产工艺
Mizagliflozin (KWA 0711)是一种新型、有效、选择性的 sodium glucose co-transporter 1 (SGLT1) 抑制剂，对human SGLT1的Ki值为27 nM。Mizagliflozin的选择性比(Ki value for human SGLT2/Ki value for human SGLT1)为303。Mizagliflozin还有改善慢性便秘的潜在应用。
| Target | Value |
human SGLT1
(Cell-free assay)
|
27 nM(Ki)
|
Mizagliflozin (DSP-3235 free base) (3-30 mg/kg; oral) exerts a laxative effect.
Mizagliflozin administrated intravenously (0.3 mg/kg) and orally (3 mg/kg) declined with a short half-life (0.23 and 1.14 h, respectively)
|
Animal Model:
|
Male Wistar rats (rat model of low-fiber-diet-induced constipation)
|
|
Dosage:
|
3, 10, 30 mg/kg
|
|
Administration:
|
Oral
|
|
Result:
|
Increased fecal wet weight in a rat model of low-fiber-diet-induced constipation.
|
Mizagliflozin
上下游产品信息
上游原料
下游产品
| 更新日期 | 产品编号 | 产品名称 | CAS编号 | 包装 | 价格 |
|---|
| 2024/04/30 | HY-17638 | Mizagliflozin | | 1 mg | 909元 |
| 2024/04/30 | HY-17638 | Mizagliflozin
Mizagliflozin | 666843-10-3 | 5mg | 2000元 |
666843-10-3, Mizagliflozin 相关搜索:
- C28H44N4O8
- DSP-3235
- 3 - ((3-(4 - ((5-异丙基-3 - (((2S,3R,4S,5S,6R)-3,4,5-三羟基-6-(羟甲基)四氢-2H-吡喃 2-基)氧基)-1H-吡唑-4-基)甲基)-3-甲基苯氧基)丙基)氨基)-2,2-二甲基丙酰胺
- 化合物MIZAGLIFLOZIN
- 666843-10-3
- KGA-3235
- KGA3235
- KGA 3235
- GSK-1614235
- GSK1614235
- GSK 1614235
- Mizagliflozin (KWA 0711)
- GSK1614235,Chronic,KGA 3235,DSP-3235,selective,Sodium-dependent glucose cotransporters,KGA-3235,constipation,Mizagliflozin,antidiabetic,disorder,SGLT,gastrointestinal,DSP 3235,inhibit,GSK 1614235,Inhibitor,KGA3235,GSK-1614235,DSP3235
- Propanamide, 3-[[3-[4-[[3-(β-D-glucopyranosyloxy)-5-(1-methylethyl)-1H-pyrazol-4-yl]methyl]-3-methylphenoxy]propyl]amino]-2,2-dimethyl-
- KGA-3235 free base
- GSK-1614235 free base
- DSP-3235 free base
- Mizagliflozin